Increase specific influenza production with recombinant human insulin

By Novo Nordisk Pharmatech A/S

Vaccines must be made in large quantities rapidly and cost-effectively. Aziza Manceur, Sonia Tremblay and Sven Ansorge from the Vaccine Program at the National Research Council Canada, with help from Novo Nordisk Pharmatech, discuss how production can be boosted by adding insulin to HEK293 cells to increase influenza virus yield.

Enter your details below to view the free white paper

By downloading this White Paper, you acknowledge that may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how Business Trade Media International Limited may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.